bestonlinecryptogames| Financial report express: Huaren Pharmaceutical's net profit for the first quarter of 2024 was 50.8229 million yuan

April twenty _ fifthBestonlinecryptogamesHuaren Pharmaceutical Co., Ltd. (300110) (300110), a listed company with A shares, released its first quarter results report in 2024. Of which, the net profit is 5082.Bestonlinecryptogames.29 million yuan, an increase of 23% over the same period last yearBestonlinecryptogames.65%.

According to the comprehensive operation and follow-up analysis of more than 1200 financial indicators of its financial data in the current period and the past five years, Huaren Pharmaceutical Company's overall financial situation in the past five years is OK according to the financial diagnosis model of flush (300033). Specifically, the operating capacity is general, growth ability and profitability are good.

Net profit was 50.8229 million yuan, an increase of 23.65% over the same period last year.

In terms of revenue and profit, the company achieved total operating income of 407 million yuan this year, an increase of 0.86% over the same period last year, and a net profit of 50.8229 million yuan, an increase of 23.65% over the same period last year, with basic earnings per share of 0.04 yuan.

In terms of assets, during the company's reporting period, the total assets at the end of the period were 5.001 billion yuan and accounts receivable were 663 million yuan; in terms of cash flow, the net cash flow generated by business activities was 111 million yuan, and the cash received by selling goods and providing services was 467 million yuan.

There are three financial highlights.

According to the relevant financial information released by Huaren Pharmaceutical Co., Ltd., there are three financial highlights in the company, as followsBestonlinecryptogames:

The average year-on-year growth rate of non-net profit deducted from the performance of the index type is 39.11%, which is excellent in the industry. The average year-on-year growth rate of growth operating profit is 37.00%, which is excellent in the industry. Inventory turnover the average inventory turnover rate is 3.33 (times / year), and the inventory liquidity is very strong.

There are two financial risks

According to the relevant financial information published by Huaren Pharmaceutical Co., Ltd., the company has two financial risks, as follows:

According to the type of indicators, the proportion of interest-paying debt is 33.71%, and there is a lot of pressure on debt repayment. The proportion of goodwill and goodwill is 16.40%, and the quality of the company's assets is poor.

Taken together, Huaren Pharmaceutical's overall financial situation is OK, with a current total score of 2.41, ranking in the middle of the 156 companies in its chemical pharmaceutical industry. Specifically, the operating capacity is general, growth ability and profitability are good.

The scores of the indicators are as follows:

Index type previous period score ranking evaluation operating ability 0.671.31116 general asset quality 0.860.54140 poor solvency 0.320.10154 lower growth ability 4.173.8836 stronger profitability 3.283.4948 good cash flow 1.152.5677 but the total score is 2.182.4179

On the large model of financial diagnosis of flush

Flush (300033) Financial diagnosis model calculates the company's financial scores, highlights and risks based on the company's latest and previous financial data and industry conditions, reflecting the company's disclosed financial position, but not a forecast of the future financial position. The financial score range is 0-5. The higher the score, the better the financial situation and the greater the value of the medium-and long-term investment. In the financial highlights and risk reviews, the five-year average of the indicators related to the "average" keyword, and the latest reporting period data without the "average" keyword. All the above information is based on artificial intelligence algorithm, for reference only, does not represent flush financial point of view, investors operate accordingly, at their own risk.

Learn more about the company's stock diagnostic information >